MDMA in Borderline Personality Disorder
ConditionBorderline Personality Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorYale University
About this trial
The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.
Eligibility criteria
Qualifiers
Adults between the ages of 18-60 years
Body weight between 110 and 210 pounds. Minimum body mass index (BMI) 16.5.
Able to swallow pills.
Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable and must sign release of information for this contact person.
Disqualifiers
History of bipolar disorder, schizophrenia or schizoaffective disorder or currently exhibiting psychotic features as determined by the Structured Clinical Interview for DSM5 (SCID-5) and/or clinician assessment.
Lifetime diagnosis of autism.
Serious suicide risk in the past 6 months, as assessed by Columbia Suicide Severity Rating Scale (CSSRS) type 4 or 5 ideation, or suicidal behavior (CSSRS item) or preparatory acts (CSSRS item).
Any current substance use disorder (in the last 1 month) per SCID interview for alcohol or non-alcohol substances; or a positive pre-study (screening) urine drug screen.
Trial design
Treatments tested in this trial
- MDMA
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
Connecticut Mental Health Center
Collaborator
Source ClinicalTrials.gov